Page 113 - 《中国药房》2024年4期

agents for patients with inflammatory bowel diseases[J]. 12（9）：1079-1088.
Clin Gastroenterol Hepatol，2019，17（9）：1655-1668.e3. [20] PAPAMICHAEL K，CHACHU K A，VAJRAVELU R K，
[11] KHAN A，BERAHMANA A B，DAY A S，et al. New et al. Improved long-term outcomes of patients with in‐
Zealand Society of Gastroenterology guidelines on therapeutic flammatory bowel disease receiving proactive compared
drug monitoring in inflammatory bowel disease[J]. N Z with reactive monitoring of serum concentrations of infli-
Med J，2019，132（1491）：46-62. ximab[J]. Clin Gastroenterol Hepatol，2017，15（10）：
[12] 中华医学会消化病学分会炎症性肠病学组.中国炎症性 1580-1588.e3.
肠病治疗药物监测专家共识意见[J]. 中华消化杂志， [21] VAUGHN B P，MARTINEZ-VAZQUEZ M，PATWARDHAN
2018，38（11）：721-727. V R，et al. Proactive therapeutic concentration monitoring
The Inflammatory Bowel Disease Group of the Gastroen‐ of infliximab may improve outcomes for patients with
terology Branch of the Chinese Medical Association. Con‐ inflammatory bowel disease：results from a pilot observa‐
sensus opinion of Chinese experts on drug monitoring for tional study[J]. Inflamm Bowel Dis，2014，20（11）：1996-
the treatment of inflammatory bowel disease[J]. Chin J 2003.
Dig，2018，38（11）：721-727. [22] AMIOT A，HULIN A，BELHASSAN M，et al. Therapeu‐
[13] MITREV N，VANDE CASTEELE N，SEOW C H，et al. tic drug monitoring is predictive of loss of response after
Review article：consensus statements on therapeutic drug de-escalation of infliximab therapy in patients with inflam‐
monitoring of anti-tumor necrosis factor therapy in in- matory bowel disease in clinical remission[J]. Clin Res
flammatory bowel diseases[J]. Aliment Pharmacol Ther， Hepatol Gastroenterol，2016，40（1）：90-98.
2017，46（11/12）：1037-1053. [23] VAN BEZOOIJEN J S，KOCH B C P，VAN DOORN M B
[14] FEUERSTEIN J D，NGUYEN G C，KUPFER S S，et al. A，et al. Comparison of three assays to quantify infli-
American Gastroenterological Association Institute guide‐ ximab，adalimumab，and etanercept serum concentrations
line on therapeutic drug monitoring in inflammatory [J]. Ther Drug Monit，2016，38（4）：432-438.
bowel disease[J]. Gastroenterology，2017，153 （3） ： [24] MARTÍN S，DEL AGUA A R，TORRES N，et al. Com‐
827-834. parison study of two commercially available methods for
[15] MELMED G Y，IRVING P M，JONES J，et al. Appro- the determination of golimumab and anti-golimumab anti‐
priateness of testing for anti-tumor necrosis factor agent body levels in patients with rheumatic diseases[J]. Clin
and antibody concentrations，and interpretation of results Chem Lab Med，2015，53（11）：e297-e299.
[J]. Clin Gastroenterol Hepatol，2016，14（9）：1302-1309. [25] STEENHOLDT C，BENDTZEN K，BRYNSKOV J，et al.
[16] HENDY P，HART A，IRVING P. Anti-TNF drug and anti‐ Clinical implications of measuring drug and anti-drug anti‐
drug antibody level monitoring in IBD：a practical guide bodies by different assays when optimizing infliximab
[J]. Frontline Gastroenterol，2016，7（2）：122-128. treatment failure in Crohn’s disease：post hoc analysis of
[17] 朱良如，沈骏. 炎症性肠病医患共同决策：一个循序渐进 a randomized controlled trial[J]. Am J Gastroenterol，
的过程[J]. 中华炎性肠病杂志，2019，3（3）：261-263. 2014，109（7）：1055-1064.
ZHU L R，SHEN J. Shared decision-making in inflamma‐ [26] BRANDSE J F，MOULD D，SMEEKES O，et al. A real-
tory bowel disease：a step-by-step process[J]. Chin J In‐ life population pharmacokinetic study reveals factors asso‐
flamm Bowel Dis，2019，3（3）：261-263. ciated with clearance and immunogenicity of infliximab in
[18] STEENHOLDT C，BRYNSKOV J，THOMSEN O Ø，et inflammatory bowel disease[J]. Inflamm Bowel Dis，
al. Individualized therapy is a long-term cost-effective 2017，23（4）：650-660.
method compared to dose intensification in Crohn’s di- [27] VERSTOCKT B，MOORS G，BIAN S M，et al. Influence
sease patients failing infliximab[J]. Dig Dis Sci，2015，60 of early adalimumab serum levels on immunogenicity and
（9）：2762-2770. long-term outcome of anti-TNF naive Crohn’s disease pa‐
[19] GUIDI L，PUGLIESE D，PANICI TONUCCI T，et al. tients：the usefulness of rapid testing[J]. Aliment Pharma‐
Therapeutic drug monitoring is more cost-effective than a col Ther，2018，48（7）：731-739.
clinically based approach in the management of loss of re- （收稿日期：2023-06-27 修回日期：2024-01-22）
sponse to infliximab in inflammatory bowel disease：an （编辑：孙 冰）
observational multicentre study[J]. J Crohns Colitis，2018，

中国药房 2024年第35卷第4期 China Pharmacy 2024 Vol. 35 No. 4 · 487 ·